Acrivon Therapeutics (NASDAQ:ACRV) Rating Lowered to Sell at Wall Street Zen

by · The Markets Daily

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

ACRV has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acrivon Therapeutics in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Acrivon Therapeutics has an average rating of “Moderate Buy” and an average target price of $11.00.

View Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Trading Down 3.1%

Shares of NASDAQ:ACRV opened at $2.53 on Friday. The company has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $1.65. The firm has a market cap of $79.85 million, a PE ratio of -1.19 and a beta of 1.75. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $8.00.

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.10. As a group, equities research analysts forecast that Acrivon Therapeutics will post -2.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Acrivon Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Focus Partners Wealth acquired a new stake in shares of Acrivon Therapeutics during the 3rd quarter worth approximately $36,000. Algert Global LLC bought a new position in Acrivon Therapeutics during the 3rd quarter worth $81,000. Two Sigma Investments LP increased its position in Acrivon Therapeutics by 76.2% in the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after buying an additional 138,033 shares during the period. UBS Group AG lifted its stake in Acrivon Therapeutics by 150,057.8% in the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after buying an additional 682,763 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Acrivon Therapeutics in the second quarter valued at $371,000. 71.62% of the stock is owned by institutional investors.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Featured Stories